cmlf-20210930
000181833112/312021Q3FALSE0.0000100018183312021-01-012021-09-300001818331us-gaap:CommonClassAMember2021-01-012021-09-300001818331us-gaap:WarrantMember2021-01-012021-09-30xbrli:shares00018183312021-11-08iso4217:USD00018183312021-09-3000018183312020-12-31iso4217:USDxbrli:shares0001818331cmlf:SeriesA1RedeemableConvertiblePreferredStockMember2020-12-310001818331cmlf:SeriesA1RedeemableConvertiblePreferredStockMember2021-09-300001818331cmlf:SeriesA2RedeemableConvertiblePreferredStockMember2021-09-300001818331cmlf:SeriesA2RedeemableConvertiblePreferredStockMember2020-12-310001818331cmlf:SeriesBRedeemableConvertiblePreferredStockMember2020-12-310001818331cmlf:SeriesBRedeemableConvertiblePreferredStockMember2021-09-300001818331cmlf:SeriesCRedeemableConvertiblePreferredStockMember2020-12-310001818331cmlf:SeriesCRedeemableConvertiblePreferredStockMember2021-09-300001818331us-gaap:CommonClassAMember2020-12-310001818331us-gaap:CommonClassAMember2021-09-300001818331us-gaap:CommonClassBMember2021-09-300001818331us-gaap:CommonClassBMember2020-12-310001818331cmlf:DiagnosticTestMembersrt:AffiliatedEntityMember2021-07-012021-09-300001818331cmlf:DiagnosticTestMembersrt:AffiliatedEntityMember2020-07-012020-09-300001818331cmlf:DiagnosticTestMembersrt:AffiliatedEntityMember2021-01-012021-09-300001818331cmlf:DiagnosticTestMembersrt:AffiliatedEntityMember2020-01-012020-09-300001818331cmlf:DiagnosticTestMember2021-07-012021-09-300001818331cmlf:DiagnosticTestMember2020-07-012020-09-300001818331cmlf:DiagnosticTestMember2021-01-012021-09-300001818331cmlf:DiagnosticTestMember2020-01-012020-09-300001818331us-gaap:ProductAndServiceOtherMembersrt:AffiliatedEntityMember2021-07-012021-09-300001818331us-gaap:ProductAndServiceOtherMembersrt:AffiliatedEntityMember2020-07-012020-09-300001818331us-gaap:ProductAndServiceOtherMembersrt:AffiliatedEntityMember2021-01-012021-09-300001818331us-gaap:ProductAndServiceOtherMembersrt:AffiliatedEntityMember2020-01-012020-09-300001818331us-gaap:ProductAndServiceOtherMember2021-07-012021-09-300001818331us-gaap:ProductAndServiceOtherMember2020-07-012020-09-300001818331us-gaap:ProductAndServiceOtherMember2021-01-012021-09-300001818331us-gaap:ProductAndServiceOtherMember2020-01-012020-09-3000018183312021-07-012021-09-3000018183312020-07-012020-09-3000018183312020-01-012020-09-300001818331srt:AffiliatedEntityMember2021-07-012021-09-300001818331srt:AffiliatedEntityMember2020-07-012020-09-300001818331srt:AffiliatedEntityMember2021-01-012021-09-300001818331srt:AffiliatedEntityMember2020-01-012020-09-300001818331us-gaap:CommonClassAMember2021-07-012021-09-300001818331us-gaap:CommonClassAMember2020-07-012020-09-300001818331us-gaap:CommonClassAMember2020-01-012020-09-3000018183312021-06-300001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-06-300001818331us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-06-300001818331us-gaap:AdditionalPaidInCapitalMember2021-06-300001818331us-gaap:RetainedEarningsMember2021-06-300001818331us-gaap:RetainedEarningsMember2021-07-012021-09-300001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-07-012021-09-300001818331us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001818331us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-07-012021-09-300001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-09-300001818331us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-09-300001818331us-gaap:AdditionalPaidInCapitalMember2021-09-300001818331us-gaap:RetainedEarningsMember2021-09-300001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-12-310001818331us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001818331us-gaap:AdditionalPaidInCapitalMember2020-12-310001818331us-gaap:RetainedEarningsMember2020-12-310001818331us-gaap:RetainedEarningsMember2021-01-012021-09-300001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-01-012021-09-300001818331us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-01-012021-09-300001818331us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-3000018183312020-06-300001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-06-300001818331us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-06-300001818331us-gaap:AdditionalPaidInCapitalMember2020-06-300001818331us-gaap:RetainedEarningsMember2020-06-300001818331us-gaap:RetainedEarningsMember2020-07-012020-09-3000018183312020-09-300001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-09-300001818331us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-09-300001818331us-gaap:AdditionalPaidInCapitalMember2020-09-300001818331us-gaap:RetainedEarningsMember2020-09-3000018183312019-12-310001818331us-gaap:CommonStockMemberus-gaap:CommonClassAMember2019-12-310001818331us-gaap:CommonClassBMemberus-gaap:CommonStockMember2019-12-310001818331us-gaap:AdditionalPaidInCapitalMember2019-12-310001818331us-gaap:RetainedEarningsMember2019-12-310001818331us-gaap:RetainedEarningsMember2020-01-012020-09-30xbrli:purecmlf:segment0001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercmlf:PayorAMember2021-07-012021-09-300001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercmlf:PayorAMember2020-07-012020-09-300001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercmlf:PayorAMember2021-01-012021-09-300001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercmlf:PayorAMember2020-01-012020-09-300001818331us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercmlf:PayorAMember2021-01-012021-09-300001818331us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercmlf:PayorAMember2020-01-012020-12-310001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercmlf:PayorBMember2020-07-012020-09-300001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercmlf:PayorBMember2020-01-012020-09-300001818331cmlf:PayorCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300001818331cmlf:PayorCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300001818331cmlf:PayorCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001818331cmlf:PayorCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercmlf:PayorDMember2020-07-012020-09-300001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercmlf:PayorDMember2021-01-012021-09-300001818331us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercmlf:PayorDMember2020-01-012020-09-300001818331us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembercmlf:PayorDMember2021-01-012021-09-300001818331cmlf:PayorEMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001818331us-gaap:CostOfGoodsTotalMembercmlf:SupplierAMemberus-gaap:SupplierConcentrationRiskMember2021-07-012021-09-300001818331us-gaap:CostOfGoodsTotalMembercmlf:SupplierAMemberus-gaap:SupplierConcentrationRiskMember2020-07-012020-09-300001818331us-gaap:CostOfGoodsTotalMembercmlf:SupplierAMemberus-gaap:SupplierConcentrationRiskMember2021-01-012021-09-300001818331us-gaap:CostOfGoodsTotalMembercmlf:SupplierAMemberus-gaap:SupplierConcentrationRiskMember2020-01-012020-09-3000018183312020-01-012020-03-310001818331cmlf:GovernmentAssistanceCARESActProviderReliefFundMember2020-01-012020-03-310001818331cmlf:GovernmentAssistanceCARESActEmployeeRetentionCreditMember2020-01-012020-03-310001818331cmlf:GovernmentAssistanceCARESActProviderReliefFundMember2021-01-012021-09-3000018183312021-07-220001818331cmlf:PublicWarrantsMember2021-07-220001818331cmlf:PrivatePlacementWarrantsMember2021-09-300001818331cmlf:PrivatePlacementWarrantsMember2021-07-220001818331us-gaap:CommonClassAMember2021-07-22cmlf:day0001818331cmlf:ClassACommonStockEqualsOrExceedsThresholdOneMember2021-01-012021-09-300001818331cmlf:ClassACommonStockEqualsOrExceedsThresholdTwoMemberus-gaap:CommonClassAMember2021-09-300001818331cmlf:ClassACommonStockEqualsOrExceedsThresholdTwoMemberus-gaap:CommonClassAMember2021-01-012021-09-300001818331cmlf:Sema4OpCoIncMember2021-01-012021-09-300001818331cmlf:Sema4OpCoIncMember2021-09-300001818331cmlf:Sema4OpCoIncMember2021-07-220001818331us-gaap:CommonClassAMembercmlf:Sema4OpCoIncMember2021-07-222021-07-220001818331us-gaap:CommonClassAMembercmlf:Sema4OpCoIncMember2021-07-220001818331us-gaap:CommonClassBMembercmlf:Sema4OpCoIncMember2021-07-222021-07-220001818331cmlf:Sema4OpCoIncMember2021-02-092021-02-090001818331cmlf:Sema4OpCoIncMember2021-02-090001818331cmlf:Sema4OpCoIncMember2021-07-222021-07-220001818331cmlf:MergerAdditionalCapitalMembercmlf:Sema4OpCoIncMember2021-07-220001818331us-gaap:PrepaidExpensesAndOtherCurrentAssetsMembercmlf:Sema4OpCoIncMember2021-07-220001818331us-gaap:CommonClassBMembercmlf:Sema4OpCoIncMember2021-07-220001818331cmlf:DiagnosticTestThirdPartyInsuranceMember2021-07-012021-09-300001818331cmlf:DiagnosticTestThirdPartyInsuranceMember2020-07-012020-09-300001818331cmlf:DiagnosticTestInstitutionalCustomersMember2021-07-012021-09-300001818331cmlf:DiagnosticTestInstitutionalCustomersMember2020-07-012020-09-300001818331cmlf:DiagnosticTestSelfPayMember2021-07-012021-09-300001818331cmlf:DiagnosticTestSelfPayMember2020-07-012020-09-300001818331cmlf:DiagnosticTestThirdPartyInsuranceMember2021-01-012021-09-300001818331cmlf:DiagnosticTestThirdPartyInsuranceMember2020-01-012020-09-300001818331cmlf:DiagnosticTestInstitutionalCustomersMember2021-01-012021-09-300001818331cmlf:DiagnosticTestInstitutionalCustomersMember2020-01-012020-09-300001818331cmlf:DiagnosticTestSelfPayMember2021-01-012021-09-300001818331cmlf:DiagnosticTestSelfPayMember2020-01-012020-09-3000018183312021-10-012021-09-300001818331us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331us-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331cmlf:PublicWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331cmlf:PublicWarrantMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331cmlf:PublicWarrantMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331us-gaap:FairValueInputsLevel3Membercmlf:PublicWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001818331us-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMember2021-09-300001818331us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMember2021-09-300001818331us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMember2021-09-300001818331us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembercmlf:PrivateWarrantMember2021-09-300001818331us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001818331us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001818331us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001818331us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001818331us-gaap:FairValueMeasurementsRecurringMember2020-12-310001818331us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001818331us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001818331us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001818331us-gaap:MeasurementInputPriceVolatilityMember2021-09-300001818331us-gaap:MeasurementInputRiskFreeInterestRateMember2021-09-3000018183312021-07-222021-09-300001818331us-gaap:EquipmentMember2021-09-300001818331us-gaap:EquipmentMember2020-12-310001818331cmlf:EquipmentHeldUnderCapitalLeaseMember2021-09-300001818331cmlf:EquipmentHeldUnderCapitalLeaseMember2020-12-310001818331us-gaap:LeaseholdImprovementsMember2021-09-300001818331us-gaap:LeaseholdImprovementsMember2020-12-310001818331us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-09-300001818331us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-12-310001818331cmlf:BuildingHeldUnderCapitalLeaseMember2021-09-300001818331cmlf:BuildingHeldUnderCapitalLeaseMember2020-12-310001818331us-gaap:ConstructionInProgressMember2021-09-300001818331us-gaap:ConstructionInProgressMember2020-12-310001818331us-gaap:ComputerEquipmentMember2021-09-300001818331us-gaap:ComputerEquipmentMember2020-12-310001818331cmlf:FurnitureFixturesAndOtherEquipmentMember2021-09-300001818331cmlf:FurnitureFixturesAndOtherEquipmentMember2020-12-3100018183312021-01-012021-06-3000018183312020-01-012020-06-300001818331us-gaap:CostOfSalesMember2021-07-012021-09-300001818331us-gaap:CostOfSalesMember2020-07-012020-09-300001818331us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001818331us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001818331us-gaap:SellingAndMarketingExpenseMember2021-07-012021-09-300001818331us-gaap:SellingAndMarketingExpenseMember2020-07-012020-09-300001818331us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001818331us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001818331us-gaap:CostOfSalesMember2021-01-012021-09-300001818331us-gaap:CostOfSalesMember2020-01-012020-09-300001818331us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001818331us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001818331us-gaap:SellingAndMarketingExpenseMember2021-01-012021-09-300001818331us-gaap:SellingAndMarketingExpenseMember2020-01-012020-09-300001818331us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001818331us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-3000018183312017-06-010001818331cmlf:RelatedPartyTSAAgreementMembersrt:AffiliatedEntityMember2021-07-012021-09-300001818331cmlf:RelatedPartyTSAAgreementMembersrt:AffiliatedEntityMember2020-07-012020-09-300001818331cmlf:RelatedPartyTSAAgreementMembersrt:AffiliatedEntityMember2021-01-012021-09-300001818331cmlf:RelatedPartyTSAAgreementMembersrt:AffiliatedEntityMember2020-01-012020-09-300001818331cmlf:RelatedPartyTSAAgreementMembersrt:AffiliatedEntityMember2021-09-300001818331cmlf:RelatedPartyTSAAgreementMembersrt:AffiliatedEntityMember2020-12-310001818331cmlf:RelatedPartyServiceAgreementsMembersrt:AffiliatedEntityMember2021-07-012021-09-300001818331cmlf:RelatedPartyServiceAgreementsMembersrt:AffiliatedEntityMember2020-07-012020-09-300001818331cmlf:RelatedPartyServiceAgreementsMembersrt:AffiliatedEntityMember2021-01-012021-09-300001818331cmlf:RelatedPartyServiceAgreementsMembersrt:AffiliatedEntityMember2020-01-012020-09-300001818331cmlf:RelatedPartyServiceAgreementsMembersrt:AffiliatedEntityMember2021-09-300001818331cmlf:RelatedPartyServiceAgreementsMembersrt:AffiliatedEntityMember2020-12-310001818331us-gaap:CostOfSalesMembersrt:AffiliatedEntityMember2021-07-012021-09-300001818331us-gaap:CostOfSalesMembersrt:AffiliatedEntityMember2020-07-012020-09-300001818331cmlf:RelatedPartyExpensesMembersrt:AffiliatedEntityMember2021-07-012021-09-300001818331cmlf:RelatedPartyExpensesMembersrt:AffiliatedEntityMember2020-07-012020-09-300001818331us-gaap:CostOfSalesMembersrt:AffiliatedEntityMember2021-01-012021-09-300001818331us-gaap:CostOfSalesMembersrt:AffiliatedEntityMember2020-01-012020-09-300001818331cmlf:RelatedPartyExpensesMembersrt:AffiliatedEntityMember2021-01-012021-09-300001818331cmlf:RelatedPartyExpensesMembersrt:AffiliatedEntityMember2020-01-012020-09-300001818331cmlf:DECDLoanAgreementMember2017-06-300001818331cmlf:DECDLoanAgreementMember2017-06-012017-06-300001818331cmlf:DECDLoanAgreementMember2021-09-300001818331cmlf:DECDLoanAgreementMember2020-12-310001818331cmlf:MasterLoanAgreementMember2020-01-012020-12-310001818331cmlf:MasterLoanAgreementMember2020-08-310001818331cmlf:MasterLoanAgreementMember2020-08-012020-08-310001818331cmlf:MasterLoanAgreementMember2020-12-310001818331cmlf:MasterLoanAgreementMember2021-01-012021-09-300001818331cmlf:MasterLeaseAgreementMember2020-12-012020-12-310001818331cmlf:MasterLeaseAgreementMember2020-12-310001818331cmlf:MasterLeaseAgreementMember2020-12-312020-12-310001818331cmlf:MasterLeaseAgreementMember2021-07-012021-07-310001818331srt:MinimumMember2021-01-012021-09-300001818331srt:MaximumMember2021-01-012021-09-300001818331srt:MinimumMember2021-09-300001818331srt:MaximumMember2021-09-30cmlf:vote0001818331cmlf:A2017StockIncentivePlanMemberus-gaap:EmployeeStockOptionMember2021-01-012021-09-300001818331cmlf:A2021PlanMember2021-07-220001818331cmlf:A2021PlanMember2021-01-012021-09-300001818331cmlf:A2021PlanMember2021-07-222021-07-220001818331cmlf:A2021PlanMember2021-07-012021-09-300001818331us-gaap:EmployeeStockMember2021-09-300001818331us-gaap:EmployeeStockMember2021-01-012021-09-300001818331cmlf:A2017StockIncentivePlanMember2021-01-012021-09-300001818331us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001818331cmlf:A2017StockIncentivePlanMemberus-gaap:CommonClassAMember2021-01-012021-09-300001818331us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001818331us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001818331us-gaap:EmployeeStockOptionMembersrt:MinimumMember2020-01-012020-09-300001818331us-gaap:EmployeeStockOptionMembersrt:MaximumMember2020-01-012020-09-300001818331us-gaap:EmployeeStockOptionMember2021-09-300001818331us-gaap:EmployeeStockOptionMembersrt:MinimumMemberus-gaap:CommonClassAMember2020-09-300001818331us-gaap:EmployeeStockOptionMembersrt:MaximumMemberus-gaap:CommonClassAMember2020-09-300001818331us-gaap:EmployeeStockOptionMemberus-gaap:CommonClassAMember2021-01-012021-09-30cmlf:employeecmlf:consultant0001818331us-gaap:StockAppreciationRightsSARSMember2021-07-012021-09-300001818331us-gaap:StockAppreciationRightsSARSMember2021-09-3000018183312021-07-222021-07-220001818331us-gaap:EmployeeStockOptionMemberus-gaap:CommonClassAMember2021-07-012021-09-300001818331us-gaap:EmployeeStockOptionMemberus-gaap:CommonClassAMember2020-07-012020-09-300001818331us-gaap:EmployeeStockOptionMemberus-gaap:CommonClassAMember2021-01-012021-09-300001818331us-gaap:EmployeeStockOptionMemberus-gaap:CommonClassAMember2020-01-012020-09-300001818331us-gaap:WarrantMember2021-07-012021-09-300001818331us-gaap:WarrantMember2020-07-012020-09-300001818331us-gaap:WarrantMember2021-01-012021-09-300001818331us-gaap:WarrantMember2020-01-012020-09-300001818331us-gaap:RedeemableConvertiblePreferredStockMember2021-07-012021-09-300001818331us-gaap:RedeemableConvertiblePreferredStockMember2020-07-012020-09-300001818331us-gaap:RedeemableConvertiblePreferredStockMember2021-01-012021-09-300001818331us-gaap:RedeemableConvertiblePreferredStockMember2020-01-012020-09-300001818331us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMember2021-11-150001818331us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMemberus-gaap:PrimeRateMember2021-11-152021-11-150001818331us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMember2021-11-152021-11-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission file number 001-39482
https://cdn.kscope.io/6d2a65b3aa6e6cbf436d6fc63b39388c-cmlf-20210930_g1.jpg
Sema4 Holdings Corp.
(Exact name of registrant as specified in its charter)
Delaware
85-1966622
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
333 Ludlow Street, North Tower, 8th Floor
Stamford, Connecticut
06902
(Address of Principal Executive Offices)(Zip Code)
(800) 298-6470
Registrant's telephone number, including area code

(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, par value $0.0001 per shareSMFRThe Nasdaq Global Select Market
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per shareSMFRWThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated fileroAccelerated filero
Non-accelerated filerxSmaller reporting companyx
Emerging growth companyx
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

The registrant had outstanding 241,261,362 shares of Class A common stock as of November 8, 2021.



Table of Contents
Page
2



CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain matters discussed in this report, including matters discussed under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “expect” and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed under the captions “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this report, as well as other factors which may be identified from time to time in our other filings with the Securities and Exchange Commission, or the SEC, or in the documents where such forward-looking statements appear. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements. Such forward-looking statements include, but are not limited to, statements about:
our estimates of the sufficiency of our existing capital resources combined with future anticipated cash flows to finance our operating requirements
our expected losses;
our expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities;
unforeseen circumstances or other disruptions to normal business operations, including supply chain interruptions and manufacturing constraints, arising from or related to COVID-19;
our expectations for generating revenue or becoming profitable on a sustained basis;
our expectations or ability to enter into service, collaboration and other partnership agreements;
our expectations or ability to build our own commercial infrastructure to scale market and sell our products;
actions or authorizations by the U.S. Food and Drug Administration or other regulatory authorities;
risks related to governmental regulation and other legal obligations, including privacy, data protection, information security, consumer protection, and anti-corruption and anti-bribery;
our ability to obtain and maintain intellectual property protection for our product candidates;
our ability to compete against existing and emerging technologies;
our stock price and its volatility;
our ability to attract and retain key personnel;
third-party payor reimbursement and coverage decisions;
our reliance on third-party laboratories and service providers for our test volume in connection with our diagnostic solutions and data programs;
our expectations for future capital requirements; and
our ability to successfully implement our business strategy.
The forward-looking statements contained in this report reflect our views and assumptions only as of the date that this report is signed. Except as required by law, we assume no responsibility for updating any forward-looking statements.
We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
3

Table of Contents
Sema4 Holdings Corp.
Condensed Consolidated Balance Sheets
(in thousands, except share amounts)
Part I - Financial Information
Item 1. Unaudited Condensed Consolidated Financial Statements
September 30, 2021 (unaudited)December 31, 2020
Assets
Current assets:
Cash and cash equivalents$461,276 $108,132 
Accounts receivable21,257 32,044 
Due from related parties413 289 
Inventory31,174 24,962 
Prepaid expenses20,205 4,557 
Other current assets4,186 4,124 
Total current assets$538,511 $174,108 
Property and equipment, net60,333 63,110 
Restricted cash900 10,828 
Other assets3,613 3,596 
Total assets$603,357 $251,642 
Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable and accrued expenses$43,079 $38,591 
Due to related parties1,425 1,425 
Current contract liabilities493 1,783 
Other current liabilities26,369 31,643 
Total current liabilities$71,366 $73,442 
Long-term debt, net of current portion11,000 18,971 
Stock-based compensation liabilities 131,989 
Other liabilities21,699 22,852 
Warrant liability46,629  
Earn-out contingent liability61,400  
Total liabilities$212,094 $247,254 
Commitments and contingencies (Note 9)
Redeemable convertible preferred stock:
Series A-1 redeemable convertible preferred stock, $0.00001 par value: 0 and 55,399,943 shares authorized, issued and outstanding at September 30, 2021 and December 31, 2020, respectively; aggregate liquidation preference of $0 and $55,000 at September 30, 2021 and December 31, 2020, respectively
 51,811 
Series A-2 redeemable convertible preferred stock, $0.00001 par value: 0 and 64,718,940 shares authorized at September 30, 2021 and December 31, 2020, respectively; 0 and 49,700,364 shares authorized, issued and outstanding at September 30, 2021 and December 31, 2020, respectively; aggregate liquidation preference of $0 and $49,342 at September 30, 2021 and December 31, 2020, respectively
 46,480 
4

Table of Contents
Sema4 Holdings Corp.
Condensed Consolidated Balance Sheets
(in thousands, except share amounts)
Series B redeemable convertible preferred stock, $0.00001 par value: 0 and 41,937,960 shares authorized, issued and outstanding at September 30, 2021 and December 31, 2020, respectively; aggregate liquidation preference of $0 and $204,302 at September 30, 2021and December 31, 2020, respectively
 118,824 
Series C redeemable convertible preferred stock, $0.00001 par value: 0 and 24,497,317 shares authorized at September 30, 2021 and December 31, 2020, respectively; 0 and 24,496,946 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively; aggregate liquidation preference of $0 and $121,397 at September 30, 2021 and December 31, 2020, respectively
 117,324 
Redeemable convertible preferred stock
 334,439 
Stockholders’ equity (deficit):
Preferred Stock, $0.0001 par value: 1,000,000 and 0 shares authorized at September 30, 2021 and December 31, 2020, respectively; 0 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively
  
Class A common stock: $0.0001 par value, 380,000,000 shares authorized, 240,190,402 shares issued and outstanding at September 30, 2021 and $0.00001 par value: 309,584,750 shares authorized, 124 shares issued and outstanding at December 31, 2020
24  
Class B convertible common stock, $0.00001 par value: 0 and 18,575,085 shares authorized at September 30, 2021 and December 31, 2020, respectively; 0 and 130,557 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively
  
Additional paid-in capital
926,253 $ 
Accumulated deficit
(535,014)(330,051)
Total stockholders’ equity (deficit)
391,263 (330,051)
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)
$603,357 $251,642 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5

Table of Contents
Sema4 Holdings Corp.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share amounts)
(unaudited)
Three months ended September 30,Nine months ended September 30,
2021202020212020
Revenue
Diagnostic test revenue (including related party revenue of $20 and $86 for the three months ended September 30, 2021 and 2020, respectively and $90 and $186 for the nine months ended September 30, 2021 and 2020, respectively)
$41,410 $37,893 $148,973 $113,759 
Other revenue (including related party revenue of $65 and $0 for the three months ended September 30, 2021 and 2020, respectively and $153 and $0 for the nine months ended September 30, 2021 and 2020, respectively)
1,768 715 5,421 1,606 
Total revenue
43,178 38,608 154,394 115,365 
Cost of services (including related party expenses of $656 and $452 for the three months ended September 30, 2021 and 2020, respectively and $1,942 and $1,485 for the nine months ended, September 30, 2021 and 2020 respectively)
58,752 36,530 180,195 111,754 
Gross (loss) profit
(15,574)2,078 (25,801)3,611 
Research and development
17,831 19,083 82,916 41,540 
Selling and marketing
22,121 12,735 69,937 33,154 
General and administrative
33,230 24,342 147,941 39,627 
Related party expenses
847 1,933 3,532 6,239 
Loss from operations
(89,603)(56,015)(330,127)(116,949)
Other income (expense), net:
Change in fair market value of warrant and earn-out contingent liabilities122,171  122,171  
Interest income
27 63 57 473 
Interest expense
(683)(637)(2,128)(1,826)
Other income (expense), net
(520)(26)5,064 2,645 
Total other income (expense), net
120,995 (600)125,164 1,292 
Income (loss) before income taxes
$31,392 $(56,615)$(204,963)$(115,657)
Income tax provision
    
Net income (loss) and comprehensive income (loss)
$31,392 $(56,615)$(204,963)$(115,657)
Weighted average shares outstanding of Class A common stock for basic earnings
185,680,394 124 63,121,738 124 
Weighted average shares outstanding of Class A common stock for diluted earnings
210,330,946 124 63,121,738 124 
Basic net income (loss) per share, Class A common stock
$0.17 $(456,573)$(3.25)$(932,718)
Diluted net income (loss) per share, Class A common stock
$0.15 $(456,573)$(3.25)$(932,718)
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6

Table of Contents
Sema4 Holdings Corp.
Condensed Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)
(in thousands, except share amounts)
(unaudited)
Three months ended September 30, 2021
Redeemable Convertible Preferred StockClass A Common StockClass B Common Stock
SharesAmountSharesPar valueSharesPar valueAdditional paid-in capitalAccumulated deficitTotal stockholders’ equity (deficit)
Balances at June 30, 2021
171,535,213$334,439 4,458$ 1,383,736$ $1,483 $(566,406)$(564,923)
Net income— — — — — — — 31,392 31,392 
Conversion of Preferred Stock(171,535,213)(334,439)148,543,062 15 — — 104,517 — 104,532 
Conversion of Class B Common Stock— — 1,309,320 — (1,383,736)— (744)— (744)
Net equity infusion from the Business Combination— — 90,333,562 9 — — 510,742 — 510,751 
Stock based compensation modification reclassification— — — — — — 304,837 — 304,837 
Stock based compensation expense— — — — — — 5,418 — 5,418 
Balances at September 30, 2021
$ 240,190,402$24 $ $926,253 $(535,014)$391,263 
Nine months ended September 30, 2021
Redeemable Convertible Preferred StockClass A Common StockClass B Common Stock
SharesAmountSharesPar valueSharesPar valueAdditional paid-in capitalAccumulated deficitTotal stockholders’ equity (deficit)
Balances at December 31, 2020171,535,213$334,439 124$ 130,557$ $ $(330,051)$(330,051)
Net loss— — — — — — — (204,963)(204,963)
Stock option exercises— — 4,334 — 1,253,179 — 1,483 — 1,483 
Conversion of Preferred Stock(171,535,213)(334,439)148,543,062 15 — 104,517 — 104,532 
Conversion of Class B Common Stock— — 1,309,320 — (1,383,736)— (744)— (744)
Net equity infusion from the Business Combination— — 90,333,562 9 — — 510,742 — 510,751 
Stock based compensation modification reclassification— — — — — — 304,837 — 304,837 
Stock based compensation expense— — — — — — 5,418 — 5,418 
Balances at September 30, 2021
$ 240,190,402$24 $ $926,253 $(535,014)$391,263 
7

Table of Contents
Sema4 Holdings Corp.
Condensed Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)
(in thousands, except share amounts)
(unaudited)
Three months ended September 30, 2020
Redeemable Convertible Preferred StockClass A Common StockClass B Common Stock
SharesAmountSharesPar valueSharesPar valueAdditional paid-in capitalAccumulated deficitTotal stockholders’ equity (deficit)
Balances at June 30, 2020
147,038,267$217,115 124$ $ $ $(147,753)$(147,753)
Net loss— — — — — — — (56,615)(56,615)
Issuance of Preferred Series C, net of issuance costs24,496,946 117,324 — — — — — —  
Balances at September 30, 2020
171,535,213$334,439 124$ $ $ (204,368)(204,368)
Nine months ended September 30, 2020
Redeemable Convertible Preferred StockClass A Common StockClass B Common Stock
SharesAmountSharesPar valueSharesPar valueAdditional paid-in capitalAccumulated deficitTotal stockholders’ equity (deficit)
Balances at December 31, 2019147,038,267$217,115 124$ $ $ $(88,711)$(88,711)
Net loss— — — — — — — (115,657)(115,657)
Issuance of Preferred Series C, net of issuance costs24,496,946 117,324 — — — — — —  
Balances at September 30, 2020
171,535,213$334,439 124$ $ $ (204,368)(204,368)
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
8

Table of Contents
Sema4 Holdings Corp.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Nine months ended September 30,
20212020
Operating activities
Net loss
$(204,963)$(115,657)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
16,012 8,147 
Stock-based compensation expense
182,454 30,073 
Change in fair value of warrant and contingent liabilities
(122,171) 
Provision for excess and obsolete inventory
1,122  
Non-cash lease expense
1,174 2,203 
Loss on extinguishment of debt301  
Change in operating assets and liabilities:
Accounts receivable
10,787 (3,159)
Inventory
(7,334)(8,105)
Prepaid expenses and other current assets
(15,710)516 
Due to/from related parties
(124)617 
Other assets
(17)1,174 
Accounts payable and accrued expenses
4,685 (537)
Contract liabilities
(1,290)(135)
Other current liabilities
(3,375)10,068 
Net cash used in operating activities
(138,449)(74,795)

Investing activities
Purchases of property and equipment
(4,344)(17,310)
Development of internal-use software assets
(8,749)(3,165)
Net cash used in investing activities
(13,093)(20,475)

Financing activities
Proceeds from issuance of Series C redeemable convertible preferred stock, net of issuance costs 117,326 
Proceeds from PIPE issuance350,000  
Proceeds from equity infusion from the merger, net of redemptions442,684  
Legacy Sema4 Shareholder payout(230,665) 
Payment of transaction costs    (51,760) 
Stock Appreciation Rights payout(3,795) 
Repayment of long-term debt(8,741) 
Capital lease principal payments(2,960)(3,384)
Long-term debt principal payments(1,000) 
Proceeds from long-term debt 6,000 
Exercise of stock options995  
Net cash provided by financing activities
494,758 119,942 

Net increase in cash, cash equivalents and restricted cash
343,216 24,672 
Cash, cash equivalents and restricted cash, at beginning of period
118,960 115,006 
Cash, cash equivalents and restricted cash, at end of period
$462,176 $139,678 
9

Table of Contents
Sema4 Holdings Corp.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

Supplemental disclosures of cash flow information
Cash paid for interest
$2,128 $1,826 
Cash paid for taxes
$50 $ 
Purchases of property and equipment in accounts payable and accrued expenses
$193 $268 
Software development costs in accounts payable and accrued expenses
$1,228 $1,629 
Assets acquired under capital leases obligations
$641 $5,637 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
10

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
1. Organization and Description of Business
Mount Sinai Genomics Inc., a Delaware corporation (“Legacy Sema4”) provides genomics-related diagnostic and information services and pursues genomics medical research. Legacy Sema4 utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. Legacy Sema4 provides a variety of genetic diagnostic tests and information with a focus on reproductive health, including pediatric, oncology and other conditions. In 2020, the Legacy Sema4 began to provide diagnostic testing services in response to the recent novel coronavirus (“COVID-19”) outbreak. Legacy Sema4 serves patients and bills third-party payors across the United States, with a substantial portion of its diagnostic testing volume occurring in New York, California, Florida, Connecticut and New Jersey.
On July 22, 2021 (the “Closing Date”), CM Life Sciences, Inc. (“CMLS”) completed the acquisition of Legacy Sema4, pursuant to that certain Agreement and Plan of Merger (as amended, the “Merger Agreement”), dated February 9, 2021. On the Closing Date, S-IV Sub, Inc. (“Merger Sub”) merged with and into the Legacy Sema4, with Legacy Sema4 surviving the merger as a wholly-owned subsidiary of CMLS (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). In connection with the consummation of the Business Combination, CMLS changed its name to “Sema4 Holdings Corp.” (“Sema4 Holdings”) and Legacy Sema4 changed its name to “Sema4 OpCo, Inc.” All equity securities of Legacy Sema4 were converted into the right to receive the applicable portion of the merger consideration.
The Merger was accounted for as a reverse recapitalization with Legacy Sema4 as the accounting acquirer and CMLS as the acquired company for accounting purposes. The shares and net loss per common share, prior to the Merger, have been retroactively restated as shares reflecting the exchange ratio established in the Merger (1 share of Legacy Sema4 Class A common stock for 123.8339 shares of Sema4 Holdings Class A common stock) (the “Conversion Ratio”).
Prior to the Merger, shares of CMLS Class A common stock, CMLS’s public warrants, and CMLS’s public units were traded on the Nasdaq Capital Market under the ticker symbols “CMLF”, “CMFLW”, and “CMLFU” respectively. On July 23, 2021, shares of Sema4 Holdings Class A common stock and Sema4 Holdings’ public warrants began trading on the Nasdaq Global Select Market (the “Nasdaq”) under the ticker symbols “SMFR” and “SMFRW,” respectively. See Note 3, “Business Combination,” for additional details.
Unless otherwise stated herein or unless the context otherwise requires, references in these notes to the “Company,” or “Sema4” refer to (i) Legacy Sema4 prior to the consummation of the Business Combination; and (ii) Sema4 Holdings and its subsidiary following the consummation of the Business Combination.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. As such, the accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto as of and for the years ended December 31, 2020, 2019 and 2018.
The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to state fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results of operations or cash flows for a full year or any subsequent interim period.
The Company’s historical financial information includes costs of certain services historically provided by Icahn School of Medicine at Mount Sinai (“ISMMS”) pursuant to the Transition Services Agreement ("TSA") and service agreements.
11

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Except as described elsewhere in Note 2 and in Note 3, “Business Combination”, there have been no material changes to the Company’s significant accounting policies as described in the unaudited condensed consolidated financial statements for the periods ended September 30, 2021 and 2020.
Although the Company has incurred recurring losses in each year since inception, the Company expects its cash and cash equivalents will be sufficient to fund operations for at least the next twelve months from the date of filing of this Form 10-Q.
Segment Information
The Company operates and manages its business as one reportable operating segment based on how the Chief Executive Officer, who is the Company’s chief operating decision maker (“CODM”), assesses performance and allocates resources across the business.
Use of Estimates
The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, the capitalization of software costs and the valuation of stock-based awards, inventory, warrant liability and earn-out contingent liability. Actual results could differ materially from those estimates, judgments and assumptions.
Concentration of Credit Risk and Other Risks and Uncertainties
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.
The Company’s cash and cash equivalents are deposited with high-quality financial institutions. The Company has balances in financial institutions that exceed federal depository insurance limits. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents.
The Company assesses both the customer and, if applicable, the third-party payor that reimburses the Company on the customer’s behalf when evaluating the concentration of credit risk. Significant customers and payors are those that represent more than 10% of the Company’s total annual revenues or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of September 30, 2021 and December 31, 2020 were primarily from large managed care insurance companies and a reference laboratory. There was no individual customer that accounted for 10% or more of the Company’s revenue or accounts receivable for any of the periods presented. The Company does not require collateral as a means to mitigate customer credit risk.
For each significant payor, revenue as a percentage of total revenues and accounts receivable as a percentage of total accounts receivable are as follows:
RevenueAccounts Receivable
Three months ended September 30,Nine months ended September 30,
As of
September 30,
As of
December 31,
202120202021202020212020
Payor A23 %22 %19 %34 %17 %10 %
Payor B
*10 %*13 %**
Payor C
15 %16 %13 %15 %**
Payor D
*12 %10 %11 %10 %*
Payor E
*****20 %
*less than 10%
12

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
The Company is subject to a concentration of risk from a limited number of suppliers for certain reagents and laboratory supplies. One supplier accounted for approximately 8% and 12% for the three months ended September 30, 2021 and 2020, respectively and 10% and 9% of purchases of lab supplies, reagents and kits for the nine months ended September 30, 2021 and 2020, respectively. This risk is managed by maintaining a target quantity of surplus stock.
Impact of COVID-19
In March 2020, the World Health Organization declared the COVID-19 outbreak a global pandemic. COVID-19 has had, and continues to have, an extensive impact on global health and economic conditions. Many jurisdictions, including those in which the Company has current operations, have implemented measures to combat the spread of COVID-19, such as travel restrictions and shelter in place orders. In addition, the healthcare sector generally experienced a decline in discretionary care services at the onset of the pandemic.
Beginning in April 2020, the Company’s diagnostic test volumes decreased significantly as compared to the prior year as a result of COVID-19 and the related limitations and priorities across the healthcare system. In response, beginning in May 2020, the Company entered into several service agreements with state governments and healthcare institutions to provide testing for the presence of COVID-19 strains. While test volumes have since improved, the Company continues to experience changes in the mix of tests due to the impact of COVID-19. COVID-19 could continue to have a material impact on the Company’s results of operations, cash flows and financial condition for the foreseeable future.
In March 2020, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law, which was a stimulus bill that, among other things, provided assistance to qualifying businesses and individuals and included funding for the healthcare system. During 2020, as part of the stimulus provided by the CARES Act, the Company received $5.4 million, comprised of $2.6 million received under the Provider Relief Fund (“PRF”) distribution, which was recognized in other income, net in the statements of operations and comprehensive loss, and $2.8 million received under the Employee Retention Credit (“ERC”) distribution, which was recorded in the other liabilities and reflected in this balance as of September 30, 2021 and December 31, 2020.
During 2021, the Company received an additional $5.6 million under the PRF distribution, which was recognized in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss.
Cash, Cash Equivalents and Restricted Cash
Cash equivalents consist of amounts invested in money market funds. Carrying values of cash equivalents approximate fair value due to the short-term nature of these instruments.
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the same amounts shown on the condensed consolidated statements of cash flows (in thousands):
As of
September 30, 2021
As of
December 31, 2020
Cash and cash equivalents$461,276 $108,132 
Restricted cash900 10,828 
Total$462,176 $118,960 
Restricted cash as of September 30, 2021 consists of money market deposit accounts that secure an irrevocable standby letter of credit that serves as collateral for security deposit operating leases (see Note 9).
Warrant Liability
As of the consummation of the Merger in July 2021, there were 21,995,000 warrants to purchase shares of Class A common stock outstanding, including 14,758,333 public warrants and 7,236,667 private placement warrants. As of September 30, 2021, there were 21,994,972 warrants to purchase shares of Class A common stock outstanding, including 14,758,305 public warrants and 7,236,667 private placement warrants outstanding. Each warrant expires five years after the Business Combination or earlier upon redemption or liquidation, and entitles the holder to purchase one share of Class
13

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
A common stock at an exercise price of $11.50 per share, subject to adjustment, at any time commencing on September 4, 2021.
The Company may redeem the outstanding public warrants if the price per share of the common stock equals or exceeds $18.00 as described below:

in whole and not in part;
at a price of $0.01 per public warrant;
upon not less than 30 days’ prior written notice of redemption to each warrant holder; and
if, and only if, the closing price of the Class A common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending three trading days before sending the notice of redemption to warrant holders.
The Company may redeem the outstanding public warrants if the price per share of the common stock equals or exceeds $10.00 as described below:

in whole and not in part;
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value of the common stock;
if, and only if, the closing price of the Class A common stock equals or exceeds $10.00 per share (as adjusted) for any 20 trading days within the 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and
if the closing price of the common stock for any 20 trading days within a 30-trading day period ending three trading days before the Company sends notice of redemption to the warrant holders is less than $18.00 per share (as adjusted), the private placement warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants, as described above.
The private placement warrants were issued to CMLS Holdings, LLC, Mr. Munib Islam, Dr. Emily Leproust and Mr. Nat Turner, and are identical to the public warrants underlying the units sold in the initial public offering, except that (1) the private placement warrants and the common stock issuable upon the exercise of the private placement warrants were not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions, (2) the private placement warrants are exercisable on a cashless basis, (3) the private placement warrants are non-redeemable (except as described above, upon a redemption of warrants when the price per share of Class A common stock equals or exceeds $10.00) so long as they are held by the initial purchasers or their permitted transferees, and (4) the holders of the private placement warrants and the common stock issuable upon the exercise of the private placement warrants have certain registration rights. If the private placement warrants are held by someone other than the initial purchasers or their permitted transferees, the private placement warrants will be redeemable by the Company and exercisable by such holders on the same basis as the public warrants.
The Company accounts for warrants as liability-classified instruments based on an assessment of the warrant terms and applicable authoritative guidance in accordance with ASC 480-Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
Earn-out contingent liability
In connection with the Merger, all Legacy Sema4 stockholders and option holders at that time became entitled to a pro rata share of 19,021,576 earn-out shares and earn-out Restricted Stock Units (“RSUs”). Based on an assessment of the earn-out shares for the Legacy Sema4 stockholders, the Company considered ASC 480 and ASC 815 and accounted for the
14

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
earn-out shares as a liability. The Company subsequently measures the fair value of the liability at each reporting period and reports the changes in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations and comprehensive loss.
The Company determined the fair value of the earn-out shares issued to the Legacy Sema4 stockholders as of September 30, 2021 was $61.4 million.
As for the earn-out RSUs for the Legacy Sema4 option holders, the vesting of such arrangement is conditioned on the satisfaction of both the service requirement and on the satisfaction of a market-based requirement. Therefore, the Company accounts for this arrangement in accordance with ASC 718- Compensation — Stock Compensation (“ASC 718”) and no amounts have been recorded in relation to the earn-out RSU during the quarter because they were not granted to the option holders during the three and nine months ended on September 30, 2021.
The estimated fair value of the earn-out is determined using a Monte Carlo valuation analysis.
Capitalized Internal-Use Software Costs
We capitalize certain costs related to the development of our software applications for internal use. Capitalization begins during the application development stage, once the preliminary project stage has been completed. If a project constitutes an enhancement to existing software, we assess whether the enhancement creates additional functionality to the software, thus qualifying the work incurred for capitalization. Costs incurred prior to meeting these criteria together with costs incurred for training and maintenance are expensed as incurred. Once the project is available for general release, capitalization ceases and we estimate the useful life of the asset and begin amortization. We exercise judgment in determining the point at which various projects may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized. We periodically assess whether triggering events are present to review internal-use software for impairment. To the extent that we change our estimates related to internal-use software, the amount of internal-use software development costs we capitalize and amortize could change in future periods.
Emerging Growth Company
The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012. As such, the Company is eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including reduced reporting and extended transition periods to comply with new or revised accounting standards for public business entities. The Company has elected to avail itself of this exemption and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
Recently Adopted Accounting Pronouncements
Effective January 1, 2021, the Company adopted Accounting Standards Update (“ASU”) 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 (“ASC 606”), Revenue from Contracts with Customers, when the counterparty is a customer. In addition, ASC Topic 808 (“ASC 808”), Collaborative Arrangements precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. Adoption of ASU 2018-18 did not have an impact on the Company’s unaudited condensed consolidated financial statements as the Company is not currently a participant in any such collaborative arrangements.
Recently Issued Accounting Pronouncements Not Yet Adopted
In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which requires lessees to recognize right-of-use assets and lease liabilities for most leases on their balance sheets. Expense recognition for lessees under ASU 2016-02 is similar to current lease accounting. ASU 2016-02 will require enhanced disclosures to help the financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The recognition, measurement and presentation of expenses and cash flows arising from a lease will primarily depend on its classification as a finance or operating lease. As an emerging growth company, the provisions of ASU 2016-02 are effective for the
15

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Company for annual and interim periods beginning after December 15, 2021. Early adoption is permitted. The Company is evaluating the transition options permissible under ASU 2016-02 and plans to adopt through a cumulative adjustment to retained earnings on the date of adoption. Significant implementation matters being addressed by the Company include documenting the new lease accounting process, and determining incremental borrowing rate and complete population of the leases for evaluation. The Company is evaluating the effect this ASU will have on its financial statements, related disclosures and ongoing financial reporting. The Company expects implementation of this ASU to result in the recognition of right-of-use assets and corresponding lease liabilities in its balance sheets, principally related to office and facility leases.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The new credit losses standard changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, contract assets recognized as a result of applying ASC 606, loans and certain other instruments, entities will be required to use a new forward looking “expected loss” model that generally will result in earlier recognition of credit losses than under today’s incurred loss model. As an emerging growth company, ASU 2016-13 is effective for annual periods beginning after December 15, 2022, with early adoption permitted. Application of the amendments is through a cumulative-effect adjustment to the opening retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company is currently evaluating the impact of the new guidance on its financial statements and related disclosures.
In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”), which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the standard. ASU 2018-15 will require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 also requires the entity (customer) to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. Additionally, ASU 2018-15 requires the entity to present the expense related to the capitalized implementation costs in the same line item in the statement of income as the fees associated with the hosting element (service) of the arrangement and classify payments for capitalized implementation costs in the statement of cash flows in the same manner as payments made for fees associated with the hosting element. The entity is also required to present the capitalized implementation costs on the balance sheets in the same line item that a prepayment for the fees of the associated hosting arrangement would be presented. The amendments in ASU 2018-15 are effective for the Company in annual reporting periods beginning after December 15, 2020 and interim periods beginning after December 15, 2021. Early adoption is permitted. The Company is expecting to prospectively apply amendments to all implementation costs incurred after the date of adoption.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company is currently assessing the impact of adopting this new accounting guidance will have on its financial statements and related disclosures.
3. Business Combination
As discussed in Note 1, on July 22, 2021, the Company consummated the Business Combination and received net cash proceeds of $510.0 million.
Pursuant to the Business Combination, the following occurred:
Holders of 10,188 shares of CMLS’s Class A common stock sold in its initial public offering (the “public shares”) exercised their right to have such shares redeemed for a full pro rata portion of the trust account holding the proceeds from CMLS’s initial public offering (the “IPO”), which was approximately $10.00 per share, or $101,880 in aggregate.
16

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Each share of CMLS’s Class B common stock was automatically converted into common stock of the Company.
Each share of the Legacy Sema4 Class B common stock was converted into 1/100th of a share of Legacy Sema4 Class A common stock and each share of Legacy Sema4 common stock and preferred stock was canceled and received a portion of the merger consideration, resulting in certain Legacy Sema4 stockholders receiving $230,665,220 of cash and the Legacy Sema4 stockholders receiving an aggregate of 178,336,298 shares of common stock of the Company.
Pursuant to subscription agreements entered into on February 9, 2021, certain investors agreed to subscribe for an aggregate of 35,000,000 newly-issued shares of common stock at a purchase price of $10.00 per share for an aggregate purchase price of $350,000,000 (the “PIPE Investment”). Concurrently with the closing of the Business Combination, the Company consummated the PIPE Investment.
After giving effect to the Merger, the redemption of public shares and the conversion of the CMLS Class B common stock as described above, and the consummation of the PIPE Investment, there were 240,190,402 shares of the Company’s common stock issued and outstanding.
The Company recorded $51.8 million of transaction costs which consist of direct, incremental legal, professional, accounting, and other third-party fees that were directly related to the execution of the Merger in additional paid-in capital. Upon consummation of the Merger, $9.0 million of the transaction costs relates to costs incurred by Legacy Sema4 and reclassed to offset against equity from prepaid expense and other current assets.
4. Revenue Recognition
Diagnostic Revenue
The majority of the Company’s revenue is generated from diagnostic services provided to three groups of customers: patients with third-party insurance coverage; patients without third-party insurance coverage or those who elect to self-pay; and institutional clients, such as hospitals, clinics and reference laboratories. Revenue from diagnostic testing services is recorded at the estimated transaction price, subject to the constraint for variable consideration, upon transfer of control of the service.
Other Revenue
The Company enters into both short-term and long-term project-based collaboration service agreements with third parties, whereby the Company provides diagnostic testing, research and related data aggregation reporting services. The consideration to which the Company is entitled pursuant to its collaboration service agreements generally includes non-refundable upfront payments and variable payments based upon the achievement of certain milestones during the contract term. Non-refundable upfront payments are generally received in advance of performing the services and, therefore, are recorded as a contract liability upon receipt. Milestone payments are included in the transaction price only when it is probable that doing so will not result in a significant reversal of cumulative revenue recognized when the uncertainty associated with the milestone is subsequently resolved. Revenue for such collaboration service agreements is recognized over time using an input measure based on costs incurred to satisfy the performance obligation.
17

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Disaggregated revenue
The following tables summarize the Company’s revenue disaggregated by type of customer (in thousands):
Three months ended September 30,
20212020
Diagnostic test revenue
Patients with third-party insurance
$36,738 $31,627 
Institutional customers
3,656 5,796 
Self-pay patients
1,016 470 
Total diagnostic test revenue
41,410 37,893 
Other revenue
1,768 715 
Total
$43,178 $38,608 
Nine months ended September 30,
20212020
Diagnostic test revenue
Patients with third-party insurance
$123,395 $103,422 
Institutional customers
23,075 8,948 
Self-pay patients
2,503 1,389 
Total diagnostic test revenue
148,973 113,759 
Other revenue
5,421 1,606 
Total
$154,394 $115,365 

Reassessment of variable consideration
Subsequent changes to the estimate of the transaction price, determined on a portfolio basis when applicable, are generally recorded as adjustments to revenue in the period of the change. The Company updates estimated variable consideration quarterly.
For the three months ended September 30, 2021, the quarterly change in estimate resulted in a net $0.6 million adjustment for tests in which the performance obligation of delivering the test results was met in prior periods. The change in estimate is a result of changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors. For the three months ended September 30, 2020, the quarterly change in estimate did not result in material adjustments to the Company’s previously reported revenue or accounts receivable amounts.
Remaining performance obligations
Due to the long-term nature of the collaboration service agreement, the Company’s obligations pursuant to such agreement represent partially unsatisfied performance obligations as of September 30, 2021. The revenues under existing collaboration service agreements with original expected durations of more than one year are estimated to be approximately $10.7 million. The Company expects to recognize the majority of this revenue over the next 4 years.
Contract assets and liabilities
Contract assets consist of the Company’s right to consideration that is conditional upon its future performance. Contract assets arise in collaboration service agreements for which revenue is recognized over time but the Company’s right to bill the customer is contingent upon the achievement of contractually-defined milestones.
Contract liabilities consist of customer payments in excess of revenues recognized. For collaboration service agreements, the Company assesses the performance obligations and recognizes contract liabilities as current or non-current based upon forecasted performance.
18

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
A reconciliation of the beginning and ending balances of contract assets and contract liabilities is shown in the table below (in thousands):
Contract
Assets
Contract
Liabilities
December 31, 2020
$2,028 $3,811 
Contract asset additions
832  
Customer prepayments
 1,723 
Revenue recognized
105 (2,076)
September 30, 2021
$2,965 $3,458 
The decrease in contract liabilities as of September 30, 2021 is primarily due to the execution of the performance obligations during the period. The Company presents contract assets and contract liabilities with respect to customer contracts on a net basis on its condensed consolidated balance sheets. As of September 30, 2021 and December 31, 2020, $0.5 million and $1.8 million is recorded as current contract liabilities, respectively.
Revenues recognized that were included in the contract liability balance at the beginning of each period were $0.3 million and $0.1 million, respectively, for the three months ended September 30, 2021 and September 30, 2020 and $2.1 million and $0.3 million for the nine months ended September 30, 2021 and September 30, 2020.
Costs to fulfill contracts
Costs associated with fulfilling the Company’s performance obligations pursuant to its collaboration service agreements include costs for services that are subcontracted to ISMMS. Amounts are generally prepaid and then expensed in line with the pattern of revenue recognition. Prepayment of amounts prior to the costs being incurred are recognized on the condensed consolidated balance sheets as current or non-current based upon forecasted performance.
As of September 30, 2021 and December 31, 2020, the Company had outstanding deferred costs to fulfill contracts of $2.2 million and $3.0 million, respectively. As of September 30, 2021 and December 31, 2020, all outstanding deferred costs were recorded as prepaid expenses and other current assets.
Amortization of deferred costs was $0.3 million and $0.2 million for the three months ended September 30, 2021 and 2020, respectively and $0.9 million and $0.7 million for the nine months ended September 30, 2021 and 2020, respectively. The amortization of these costs is recorded in the cost of services on the condensed consolidated statements of operations and comprehensive loss.
5. Fair Value Measurements

Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. The following hierarchy lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.

Level 2: Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active or model-derived valuations whose significant inputs are observable.
Level 3: Unobservable inputs that are significant to the measurement of fair value but are supported by little to no market data.
19

Table of Contents
Sema4 Holdings Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
The Company’s financial assets and liabilities consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, capital leases, warrant liability, earn-out contingent liability and long-term debt. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the relatively short-term nature of these accounts.
The Company’s capital leases and long-term debt are classified within Level 1 of the fair value hierarchy because such long-term debt and capital lease agreements bear interest at rates for instruments with similar characteristics; accordingly, the carrying value of these liabilities approximate their fair values.
The following tables set forth the fair value of financial instruments that were measured at fair value on a recurring basis (in thousands):
As of September 30, 2021
TotalLevel 1Level 2Level 3
Financial Assets:
Money market funds
$451,784 $451,784 $ $ 
Total financial assets
$451,784 $451,784 $ $ 
Financial Liabilities:
Public warrant liability
$31,287 $31,287 $ $ 
Private warrant liability
15,342  15,342  
Earn-out contingent liability61,400   61,400 
Total financial liabilities
$108,029 $31,287 $15,342 $61,400